Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3025–3048 of 4,253 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK1349572; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bacterial Vaginosis
Interventions: GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Obstructive Sleep Apnea
Interventions: 8mg dexamethasone; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Stress Urinary Incontinence
Interventions: lidocaine with epinephrine, Normal saline with epinephrine; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Bethel Park, Pennsylvania • Jefferson Hills, Pennsylvania • Pittsburgh, Pennsylvania + 1 more

Conditions: Alzheimer Disease
Interventions: Simufilam, Placebo; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 87 Years
Enrollment: 1,125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 65
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 57 more

Conditions: Hypertension
Interventions: Minocycline; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cardiovascular Disease
Interventions: EVARREST™, Topical hemostat, Standard of Care; Biological · Other
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: Azacitidine, Pre-DLI Salvage Chemotherapy, Donor Leukocyte Infusion (DLI); Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, aleglitazar; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Chino, California • Los Angeles, California • Santa Ana, California + 20 more

Conditions: Cigarette, Smoking Behaviors, Cigarette Smoking Behavior
Interventions: Mentholated cigarette sampling, Hypothetical Policy Scenarios, Subjective value assessment; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Excessive Sleepiness
Interventions: Armodafinil, Matching Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more

Conditions: HIV
Interventions: PATH For Triples, Treatment as Usual; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Muscle Atrophy, Surgery, Knee Injuries and Disorders, Complication of Surgical Procedure, Trauma
Interventions: Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection; Drug · Other
Lead sponsor: The Stone Research Foundation for Sports Medicine and Arthritis; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cataract
Interventions: CVisc50 OVD, ProVisc OVD, Cataract Surgery; Device · Procedure
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 45 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 22
States / cities: Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 18 more

Conditions: Peripheral Arterial Disease
Interventions: Ixmyelocel-T, Placebo; Biological
Lead sponsor: Vericel Corporation; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 16 more

Conditions: Healthy Volunteers
Interventions: MGTA-145, plerixafor, Placebo; Biological
Lead sponsor: Ensoma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Tendinopathy
Interventions: Adipose Stem/Stromal Cells for Enthesis/Tendon Therapy (ASSET) Injection; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Arterial Hypertension
Interventions: inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Dental Plaque Accumulation
Interventions: MIIP-E2 containing gum, placebo gum without MIIP-E2; Device
Lead sponsor: Lactea Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Kidney Diseases, High Cholesterol
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Conditions: Healthy
Interventions: Oxycodone controlled-release test formulation, Immediate-release reference drug; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Antihistamine, Methylprednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 24
States / cities: Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more

Conditions: Homocystinuria
Interventions: SYNB1353; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Peripheral Arterial Disease
Interventions: Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter, EverCross Percutaneous Transluminal Balloon Catheter; Device
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 42
States / cities: Yuma, Arizona • Fremont, California • Los Angeles, California + 37 more

Search by objective public record fields.

GSK1349572 Hepatic Impairment Study

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

Post-Operative Steroids After Sleep Surgery

The Impact of Retropubic Lidocaine vs Saline on Postoperative Urinary Retention Following Midurethral Sling

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Study 3: Minocycline Decreases Microglia Activation

The Fibrin Pad Cardiovascular Study

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

An Experimental Evaluation of Menthol-Flavored Tobacco Accessories

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

PATH For Triples Study: Medication and Lifestyle Adherence for HIV+ Patients

Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study

A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

Autologous Fat Grafting for the Treatment of Chronic Tendinopathy

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

4-day Plaque Accumulation Model Evaluating Compound Containing Gum

Evolocumab In Advanced Chronic Kidney Disease Trial

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon